Winrevair Trial Could Recast Merck's Growth Story In Pulmonary Hypertension [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk test, a key functional measure in this condition. Positive findings could support advancement to phase 3 trials and broaden Merck's participation in the pulmonary hypertension market. For you as an investor following NYSE:MRK, Winrevair sits outside the company's more familiar franchises in oncology and HIV and targets a high value cardiovascular and respiratory disease area. Pulmonary hypertension treatments often aim to improve exercise capacity and daily functioning, so the 6 minute walk test data will be a central focus once results are released. This upcoming readout could influence how you think about Merck's future mix of therapies and its research focus beyond current pillars. The outcome may help clarify
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Keytruda's reign continues; pharma's megadeal drought [Yahoo! Finance]Yahoo! Finance
- ????????????????: 2036????????? [CNET News]CNET News
- Merck's WELIREG Kidney Cancer Trials Deepen Oncology Growth Story [Yahoo! Finance]Yahoo! Finance
- Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) had its price target raised by Wells Fargo & Company from $135.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website